Annual Congress Berlin 2001

Saturday, 22.09.2001
Sunday, 23.09.2001
Monday, 24.09.2001
Tuesday, 25.09.2001
Wednesday, 26.09.2001

Citations should be made in the following way: Authors. Title. Eur Respir J 2004; 18: Suppl. 33, abstract number.

Material from 2001:

3025 Abstracts

Material from 2001: Show

Safety and efficacy of inhaled corticosteroids in childhood asthma

Thematic Poster Session
Chairs: K-H. Carlsen (Oslo, Norway), S. Pedersen (Kolding, Denmark)

Download all media

High steroid burden in children with asthma and nasal symptoms D. S. Ekins-Daukes, C. R. Simpson, P. J. Helms, M. W. Taylor, J. S. McLay (Aberdeen, United Kingdom)
Fluticasone propionate in asthmatic children: a long term dose comparison of safety and efficacy E. Verona, D. Petrov, E. Cserhati, J. Hofman, N. Geppe, P. Davies (Zagreb, Croatia; Varna, Bulgaria; Budapest, Hungary; Bialystok, Poland; Moscow, Russia; Uxbridge, United Kingdom)
Flunisolide HFA has no effects on growth in children with asthma M. Boguienewicz, K. Newman (Denver, New York, United States Of America)
Flunisolide HFA demonstrates long-term safety vs two comparator drugs in the paediatric setting K. Newman, M. Boguniewicz (New York, Denver, United States Of America)
Randomised, double-blind, double-dummy, parallel-group comparison of the effect of fluticasone propionate (FP) 100 μg bd and budesonide (BUD) 200 μg bd on childhood growth: protocol and baseline characteristics A. C. Ferguson, H. P. Van Bever, A. M. Teper, O. Lasytsya, P. J. Whitehead (Vancouver, Canada; Antwerpen, Belgium; Buenos Aires, Argentina; Kiev, Ukraine; Uxbridge, United Kingdom)
Helsinki early intervention childhood asthma (HEICA) study: periodic budesonide (Pulmicort Turbuhaler®) treatment was associated with fast catch-up growth M. Turpeinen, The HEICA Study Group (Helsinki, Finland)
Urinary cortisol levels following 400 mcg budesonide twice daily from a novel multi-dose dry powder inhaler compared to a conventional dry powder inhaler in children M. Kowalski, J. Alkiewicz, A. Emeryk, M. Davison (Lodz, Poznan, Lublin, Poland; Leiderdorp, The Netherlands)
High doses of inhaled fluticasone propionate dose-dependently suppress adrenal cortical function in asthmatic children M. J. Visser, E. J. Duiverman, D. S. Postma, L. R. Arends, P. L. P. Brand (Groningen, Zwolle, The Netherlands)
Effect of administration of intranasal fluticasone propionate on lower leg growth rate in children with rhinitis L. Agertoft, S. Pedersen (Kolding, Denmark)
Steroid sparing effect and the influence on height of Montelukast therapy in the treatment of asthmatic children: a retrospective observational study S. El-Neil, A. Parker, J. Pool, R. Ross-Russell, R. Iles (Cambridge, United Kingdom)
Reduction in percent of days with asthma symptoms and activity limitation in young asthmatic children treated with Montelukast J. M. Arduino, N. C. Santanello, B. A. Knorr (West Point, United States Of America)
Posterior subcapsular opacities not observed in children treated for 18 months with budesonide Turbuhaler® M. Turpeinen, O. Kari, The HEICA Study Group (Helsinki, Finland)
Lack of cataracts and other localized adverse events in children treated with nebulized budesonide inhalation suspension S. Szefler, S. Fitzpatrick, M. Cruz-Rivera, E. Lyzell (Denver, Wayne, Wilmington, United States Of America)
Adrenal function and bone turnover in asthmatic children K. A. Khalik, M. A. Abd El Fattah, E. M. Fouda, M. A. Shaheen, A. A. El Sebai (Cairo, Egypt)
Formoterol Turbuhaler® reduces the need for relief medication in children with mild to moderate asthma and improves quality of life P. R. Everden, V. Manion, S. Reynia, On behalf of the FACT Study Investigators' Group (North Walsham, Norfolk, Kings Langley, United Kingdom)